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Healthcare Professionals Warned Not To Use Certain Intravenous 
Metronidazole, Ondansetron, and Ciprofloxacin Due To Potential 
Contamination
Summary
The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals not to use certain 
intravenous (IV) bags of metronidazole, ondansetron, and ciprofloxacin because of potential 
contamination. FDA has received reports of floating matter in IV bags manufactured by Claris 
Lifesciences Limited, in Ahmedabad, India. Microbiological analysis identified the matter in one of the 
bags as a Cladosporium mold. Molds of this type can cause infections in susceptible patients, such as 
immunocompromised individuals. At this time, FDA is not aware of any reports of injuries due to 
administration of these products. Affected products include any metronidazole, ondansetron, and 
ciprofloxacin manufactured by Claris Lifesciences Limited and sold under the following labels: Claris, 
Sagent Pharmaceuticals, Pfizer, West-Ward Pharmaceuticals.
Background
Metronidazole and ciprofloxacin are antibiotics used to treat a variety of infections. Ondansetron is an 
antiemetic used to treat nausea and vomiting associated with chemotherapy or surgery. A complaint of 
white matter in a bag of metronidazole was received, and subsequent microbiological analysis identified 
the matter as a Cladosporium mold. Molds of this type can cause infections in susceptible patients, such 
as immunocompromised individuals. Another complaint of white matter in a bag of ondansetron was 
received and that bag is currently under analysis. Foreign matter should not be present in a sterile 
injectable product.
Recommendations
While FDA is learning more about the situation, healthcare professionals should NOT use and should 
immediately remove from their pharmacy inventories any metronidazole, ondansetron, and ciprofloxacin 





Only metronidazole, ciprofloxacin, and ondansetron in IV bags sold under the Claris, Sagent, Pfizer, and 
West-Ward Pharmaceuticals labels are affected. Claris is initiating a recall of all lots of these products. 
These products were all manufactured on the same production line.
For patients who have received any one of these products, clinicians are advised to stop usage 
immediately and observe patients for any signs of new infection (e.g., fevers or chills). Clinicians are 
requested to report any suspected adverse events following use of these products to FDA's MedWatch 
program at 1-800-332-1088 or http://www.fda.gov/medwatch. On May 17, 2010, FDA posted an 
announcement that Sagent Pharmaceuticals, Inc. had announced a voluntary recall of specific lots of 
metronidozole injection (see http://www.fda.gov/Safety/Recalls/ucm212302.htm). Today's HAN Advisory 
announces a recall initiated by Claris covering all lots of the three affected products (metronidazole, 
ciprofloxacin, and ondansetron) manufactured by Claris and sold under the labels Claris, Sagent, West­
Ward, and Pfizer.
For More Information:
• FDA intends to provide new information when it becomes available. Clinicians with additional 
questions may contact the FDA at 1-888-463-6332 or druginfo@fda.hhs.gov
• Additional information is available at: http://www.fda.gov
The Centers for Disease Control and Prevention (CDC) protects people's health and safety by 
preventing and controlling diseases and injuries; enhances health decisions by providing credible 
information on critical health issues; and promotes healthy living through strong partnerships with
local, national and international organizations.
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